Hum. Reprod. Advance Access originally published online on March 3, 2006
Human Reproduction 2006 21(7):1884-1893; doi:10.1093/humrep/del052
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pretreatment with transdermal testosterone may improve ovarian response to gonadotrophins in poor-responder IVF patients with normal basal concentrations of FSH
1 Institut Clínic of Gynecology, Obstetrics and Neonatology and 2 Hormonal Laboratory, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
3 To whom correspondence should be addressed at: Institut Clínic of Gynecology, Obstetrics and Neonatology, Hospital Clínic-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/Casanova 143, 08036-Barcelona, Spain. E-mail: jbalasch{at}ub.edu
BACKGROUND: Treatment of poor-responder patients to controlled ovarian stimulation for assisted reproduction, who have normal basal FSH concentrations, is one of the most difficult challenges in reproductive medicine. This study investigated the usefulness of testosterone pretreatment in such patients. METHODS: Prospective, therapeutic, self-controlled clinical trial including 25 consecutive infertile patients who had a background of the first and second IVF treatment cycle cancellations due to poor follicular response, in spite of vigorous gonadotrophin ovarian stimulation and having normal basal FSH levels. In the third IVF attempt, all patients received transdermal testosterone treatment (20 µg/kg per day) during the 5 days preceding gonadotrophin treatment. RESULTS: Twenty patients (80%) showed an increase of over fivefold in the number of recruited follicles, produced 5.8 ± 0.4 (mean ± SEM) oocytes, received two or three embryos and achieved a clinical pregnancy rate of 30% per oocyte retrieval. There were 20% cancelled cycles. CONCLUSION: Pretreatment with transdermal testosterone may be a useful approach for women known to be low responders on the basis of a poor response to controlled ovarian stimulation but having normal basal FSH concentrations.
Key words: androgens/IVF/low responders
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Lossl, C. Y. Andersen, A. Loft, N.L.C. Freiesleben, S. Bangsboll, and A. N. Andersen Short-term androgen priming by use of aromatase inhibitor and hCG before controlled ovarian stimulation for IVF. A randomized controlled trial Hum. Reprod., May 15, 2008; (2008) den131v1. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Nelson, R. W. Yates, and R. Fleming Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles implications for individualization of therapy Hum. Reprod., September 1, 2007; 22(9): 2414 - 2421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Sipe and B. J. Van Voorhis Testosterone patch improves ovarian follicular response to gonadotrophins in a patient with Kallmann's syndrome: A Case Report Hum. Reprod., May 1, 2007; 22(5): 1380 - 1383. [Abstract] [Full Text] [PDF]
|
|